Analysts Set Tocagen Inc (NASDAQ:TOCA) PT at $16.00

Shares of Tocagen Inc (NASDAQ:TOCA) have earned an average recommendation of “Buy” from the eleven ratings firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $14.46.

TOCA has been the topic of a number of recent research reports. Cantor Fitzgerald initiated coverage on Tocagen in a report on Thursday, April 25th. They issued an “overweight” rating and a $28.00 target price on the stock. Leerink Swann set a $5.00 target price on Tocagen and gave the stock a “hold” rating in a report on Wednesday, May 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Tocagen in a report on Friday, August 9th. Zacks Investment Research raised Tocagen from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Wednesday. Finally, ValuEngine raised Tocagen from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Shares of NASDAQ TOCA traded up $0.04 during midday trading on Friday, hitting $4.34. 4,543 shares of the stock traded hands, compared to its average volume of 174,162. The stock has a 50-day moving average price of $5.58. The stock has a market capitalization of $112.56 million, a price-to-earnings ratio of -1.78 and a beta of 3.90. The company has a quick ratio of 5.05, a current ratio of 5.05 and a debt-to-equity ratio of 0.75. Tocagen has a one year low of $4.12 and a one year high of $15.80.



Tocagen (NASDAQ:TOCA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.04. Tocagen had a negative return on equity of 107.89% and a negative net margin of 300.42%. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.50 million. On average, equities analysts anticipate that Tocagen will post -2.78 earnings per share for the current year.

In related news, Director Faheem Hasnain bought 43,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The shares were bought at an average cost of $4.66 per share, with a total value of $200,380.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders purchased 53,000 shares of company stock worth $244,880. 10.90% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of the business. Beaumont Financial Partners LLC raised its holdings in Tocagen by 10.4% during the first quarter. Beaumont Financial Partners LLC now owns 14,999 shares of the company’s stock valued at $163,000 after acquiring an additional 1,413 shares during the period. Rhumbline Advisers raised its holdings in Tocagen by 9.4% during the first quarter. Rhumbline Advisers now owns 25,491 shares of the company’s stock valued at $277,000 after acquiring an additional 2,188 shares during the period. Bank of America Corp DE raised its holdings in Tocagen by 28.6% during the fourth quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock valued at $120,000 after acquiring an additional 3,240 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Tocagen by 8.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 50,940 shares of the company’s stock valued at $341,000 after acquiring an additional 3,767 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Tocagen by 7.7% during the fourth quarter. Bank of New York Mellon Corp now owns 56,938 shares of the company’s stock valued at $468,000 after acquiring an additional 4,093 shares during the period. 35.06% of the stock is currently owned by institutional investors and hedge funds.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

See Also: Book Value Per Share in Stock Trading

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.